


Neonatal Hypoxic – Ischemic Encephalopathy

Treatment Approaches from Evidence



Dr. Nguyen Pham Minh Tri – NICU – Children's Hospital 2


Content

1. Introduction
2. HIE and Hypothermia
3. Other combination treatments
4. Conclusion



HIE in the world

- Major public health issue
- 23% of the total 4 M deaths in the world
- 20% of global incidence of cerebral palsy



Lawn JE et al, Lancet 2005



Etiologies of HIE

■ Maternal


- Cardiac arrest
- Asphyxiation
- Severe anaphylaxis
- Status epilepticus
- Hypovolemic shock

■ Uteroplacental

- Placental abruption
- Cord prolapse
- Uterine rupture
- Hyperstimulation with oxytocic agents

■ Fetal

- Fetomaternal haemorrhage
- Twin to twin transfusion
- Severe iso-immune haemolytic disease
- Cardiac arrhythmia



HIE severity and morbidity/mortality

Moderately severe

Severe

- **1-3 / 1000** livebirths
- Severe handicaps: **30-50%**
(epilepsy, cognitive impairment, CP...)
- Mild handicaps: **10-20%**
- Normal outcome at 2y: **30-40%**

- **0.5-2 / 1000** livebirths
- Neonatal mortality: **50-75%**
- Severe handicaps: **80%**
- Mild handicaps: **10-20%**
- Normal outcome at 2y: **10%**



Early evaluation of HIE


- Early, **repeated** clinical examination: **Sarnat staging+++**
- Clinical investigations:
 - **EEG**: early, continuous recording / standard EEG or aEEG
 - **Ultrasonography**: easy but non specific, *as early as possible*
- Short term prognosis. **HYPOTHERMIA?**
 - **MRI**: standard sequences + Diffusion +/- DTI + MRSpectroscopy: *btw day 3 - day 8 +/- day 10-15*
- Long term outcome.



Sarnat grading scale for HIE

| | Grade 1 (mild) | Grade 2 (moderate) | Grade 3 (severe) |
|-------------------------------|------------------------------------|-----------------------------------|---|
| Level of consciousness | Irritable/hyperalert | Lethargy | Coma |
| Muscle tone | Normal or hypertonia | Hypotonia | Flaccid |
| Tendon reflexes | Increased | Increased | Depressed or absent |
| Seizures | Absent | Frequent | Frequent |
| Complex reflexes | Normal | weak | Absent |
| Prognosis | Good (100%) Normal | Variable (80%) Normal | High mortality and neurological disability (50% Death 50% major sequelae) |


Amplitude EEG features in HIE



From Thoresen M, et al. Effect of hypothermia on amplitude-integrated electroencephalogram in infants with asphyxia. *Pediatrics*. 2010 Jul;126(1):e131-9. PMID:9563847 Reprinted with permission of The American Academy of Pediatrics




HIE and MRI features



- Basal ganglia and thalami
- Cortical enlighting
- Post limb of internal capsule
- White matter

normal



Rutherford et al., Lancet 2010







Figure 1: Mechanisms of evolving neural injury in HIE



HIE and energy failures




- First energy failure during HIE
- Rapid recovery
- Secondary energy failure after 6-12h post HIE
- Mitochondrial insult
- Cell death and apoptosis

The ratio of inorganic phosphate (Pi) to phosphocreatine (PCr) is validated marker of mitochondrial function.




Brain metabolism is normal following resuscitation but deteriorates later



Azzopardi et al. Pediatr Res 1989;25:445-451

Hypothermia: concept



- To induce a stable central temperature around $33.5 \pm 0.5 \text{ } ^\circ\text{C}$
- Before 6 hours of life
- In the most stable manner
- For a 72h duration
- Progressive and cautious rewarming $0.2 \text{ } ^\circ\text{C / h}$



Hypothermia: cellular effects

- ↘ cerebral metabolism → ↘ edema
- ↘ energy utilization
- ↘ cytotoxic amino acid accumulation (glutamate) and nitric oxide
- ↘ platelet-activating factor → ↘ inflammatory cascade
- ↘ secondary neuronal damage and cell death
- ↘ extent of brain damage
- ↘ blood brain barrier dysruption



Experimental evidence supporting therapeutic hypothermia

- Hypothermia applied *after* HIE:
 - **Reduces elevation of dopamine, free fatty acid and glutamate**
 - Stroke 1989 ;20:904-10.
 - **Preserves cerebral energy metabolism**
 - Pediatr Res 1995 ;37:667-670; Pediatr Res 1997 ;41:803-808
 - **Reduces the delayed increase in extracellular glutamate**
 - Neuroreport 1997 ;8:3359-62
 - **Reduces the secondary rise in cortical impedance (cytotoxic oedema)**
 - Pediatrics 1998 ;102:1098-1106
 - **Inhibits apoptotic cell death**
 - Neuropathol Appl Neurobiol 1997 ;23:16-25




Hypothermia



Head cooling or
total body cooling




Hypothermia criteria



Beneficial effect of hypothermia according to HIE severity


| Study or Subgroup | Hypothermia | | Normothermia | | Weight, % | Risk Ratio M-H, Fixed (95% CI) |
|--|-------------|------------|--------------|------------|--------------|-----------------------------------|
| | Events | Total | Events | Total | | |
| Infants With Moderate Encephalopathy | | | | | | |
| Azzoparadi et al, ¹³ 2009 | 20 | 65 | 30 | 67 | 17.9 | 0.69 (0.44-1.08) |
| Gluckman et al, ¹⁰ 2005 | 28 | 62 | 39 | 69 | 22.3 | 0.80 (0.57-1.13) |
| Gunn et al, ³² 1998 | 4 | 10 | 1 | 5 | 0.8 | 2.00 (0.30-13.51) |
| Jacobs et al, ²⁰ 2011 | 26 | 61 | 34 | 51 | 22.4 | 0.64 (0.45-0.91) |
| Shankaran et al, ¹² 2005 | 22 | 69 | 30 | 63 | 19.0 | 0.67 (0.43-1.03) |
| Simbruner et al, ²¹ 2010 | 6 | 19 | 9 | 15 | 6.1 | 0.53 (0.24-1.15) |
| Zhou et al, ²² 2010 | 9 | 41 | 19 | 41 | 11.5 | 0.47 (0.24-0.92) |
| Subtotal (95% CI) | | 327 | | 311 | 100.0 | 0.67 (0.56-0.81) |
| Total events | 115 | | 162 | | | |
| Heterogeneity: $\chi^2_6 = 3.75$; $P = .71$; $I^2 = 0\%$ | | | | | | |
| Test for overall effect: $z = 4.27$; $P < .001$ | | | | | | |
| Infants With Severe Encephalopathy | | | | | | |
| Azzoparadi et al, ¹³ 2009 | 54 | 98 | 56 | 95 | 26.8 | 0.93 (0.73-1.19) |
| Gluckman et al, ¹⁰ 2005 | 28 | 40 | 32 | 35 | 16.1 | 0.77 (0.61-0.96) |
| Gunn et al, ³² 1998 | 2 | 3 | 3 | 3 | 1.6 | 0.71 (0.31-1.66) |
| Jacobs et al, ²⁰ 2011 | 25 | 30 | 24 | 27 | 11.9 | 0.94 (0.76-1.15) |
| Shankaran et al, ¹² 2005 | 23 | 32 | 34 | 40 | 14.2 | 0.85 (0.66-1.09) |
| Simbruner et al, ²¹ 2010 | 21 | 34 | 39 | 43 | 16.2 | 0.68 (0.51-0.90) |
| Zhou et al, ²² 2010 | 22 | 38 | 27 | 35 | 13.2 | 0.75 (0.54-1.04) |
| Subtotal (95% CI) | | 275 | | 278 | 100.0 | 0.83 (0.74-0.92) |
| Total events | 175 | | 215 | | | |
| Heterogeneity: $\chi^2_6 = 5.12$; $P = .53$; $I^2 = 0\%$ | | | | | | |
| Test for overall effect: $z = 3.46$; $P < .001$ | | | | | | |



Tagin et al., Cochrane 2012


NNT 6-8

Beneficial effect of hypothermia according to cooling technique



Tagin et al., Cochrane 2012

Normal outcome following hypothermia for HIE



Tagin et al., Cochrane 2012

Impact of hypothermia on MRI findings

| | Cooled (n=64) | Non-cooled (n=67) | Adjusted* | | Unadjusted* | |
|---|------------------|----------------------|------------------|------|------------------|------|
| | | | OR (95% CI) | p | OR (95% CI) | p |
| Basal ganglia and thalami: | | | | | | |
| 0 | 26 | 14 | 0.36 (0.15-0.84) | 0.02 | 0.39 (0.18-0.84) | 0.02 |
| 1 | 11 | 14 | | | | |
| 2 | 11 | 14 | | | | |
| 3 | 16 | 25 | | | | |
| Posterior limb of internal capsule | | | | | | |
| Normal | 34 | 23 | 0.38 (0.17-0.85) | 0.02 | 0.46 (0.23-0.93) | 0.03 |
| Equivocal | 2 | 5 | | | | |
| Abnormal | 28 | 39 | | | | |
| White matter: | | | | | | |
| Normal | 23 | 11 | 0.30 (0.12-0.77) | 0.01 | 0.35 (0.15-0.80) | 0.01 |
| 1 | 19 | 26 | | | | |
| 2 | 15 | 21 | | | | |
| 3 | 7 | 9 | | | | |
| Cortex† | | | | | | |
| 0 | 34 | 24 | 0.62 (0.27-1.41) | 0.25 | 0.65 (0.29-1.42) | 0.28 |
| 1 | 16 | 22 | | | | |
| 2 | 10 | 16 | | | | |
| 3 | 4 | 4 | | | | |
| Intracranial haemorrhage | 25 | 22 | Not done | | 1.31 (0.64-2.68) | 0.11 |

Data are number or OR (95% CI). *Odds ratio for presence or absence of MRI abnormalities in cooled and non-cooled infants, with and without adjustment for severity of amplitude integrated EEG and postnatal age. OR=odds ratio.
†Cortex could not be assessed in one infant in the non-cooled group.

Table 2: Grades of cerebral lesions seen on MRI in cooled and non-cooled infants

THERAPEUTIC
HYPOTHERMIA
reduces basal
ganglia and WM
lesions
BUT
has NO effect on
cortical damage



Mid- long-term outcomes: neurocognitive/behavior scales

- **12-30 months: Bayley**
 - (Eicher & al., 2004; Jacobs & al., 2011; Shankaran & al., 2005)
- **6-7 years: WPPSI-III / WISC-IV / NEPSY / M-ABC**
 - (Marlow & al., 2005; Shankaran & al., 2012)
- **9-10 years: WISC-III / M-ABC / CBCL**
 - (de Veries & Jongmans, 2010)



Childhood outcomes after hypothermia for HIE

- **Objective**

- Long term evaluation (6-7 y) of infants having experienced hypothermia for HIE

- **Methods and patients**

- 208 infants with HIE 2-3 at birth
- 93 controls (6y8m) vs 97 hypothermia (6y7m)
- 18 lost (15% of surviving)
- Motor : GMFCS / Intellect : WPPSI-III & WISC-IV / Attention, FE, Visuospatial: NEPSY / Emotional & Social : Child Health Questionnaire



Childhood outcomes after hypothermia for HIE


• Results

– Hypothermia (n = 97)

- 27 deaths (28 %)
- 5 lost (5 %)
- 12/69 CP (17 %)
- 1/67 blindness (1 %)
- 3/63 deafness (5%)

– Controls (n = 93)

- 41 deaths (44 %)
- 13 lost (14 %)
- 15/52 CP (29 %)
- 2/50 blindness (4 %)
- 1/50 deafness (2%)



Childhood outcomes after hypothermia for HIE

- **Results**

- **Hypothermia**


- 19/70 IQ < 70 (27 %)
 - 2/48 dysexecutive functions (< 70) (4 %)
 - 2/53 visuo-spatial impairment (< 70) (4 %)

- **Controls**

- 17/52 IQ < 70 (33 %)
 - 4/32 dysexecutive functions (< 70) (13 %)
 - 1/36 visuo-spatial impairment (< 70) (3 %)



Hypothermia + neuroprotective agents



Robertson et al., 2012



Promising candidate molecules to be associated with hypothermia

| | Melatonine | Epo | NAC | Epo mimetics | Allopurinol | Xenon | Vit C&E | Memantine | Topiramate | Adenosine A2A rec antag |
|-----------------|----------------|----------------|----------------|----------------|----------------|----------------|----------------|----------------|----------------|-------------------------|
| Easy to use | 10 | 10 | 10 | 10 | 7 | 4 | 9 | 3 | 4 | 5 |
| Regimen | 7 | 7 | 7 | 7 | 8 | 6 | 6 | 5 | 4 | 5 |
| SAE | 10 | 8 | 10 | 8 | 8 | 8 | 6 | 6 | 5 | 8 |
| Toxicity | 10 | 10 | 10 | 7 | 10 | 8 | 8 | 10 | 9 | 2 |
| Benefits | 8 | 8 | 3 | 6 | 3 | 8 | 4 | 3 | 3 | 5 |
| FDA approval | yes | yes | yes | no | yes | no | yes | yes | yes | no |
| Total score /50 | 45 | 43 | 40 | 38 | 36 | 34 | 33 | 27 | 25 | 22 |
| Rank % score | 1 (90%) | 2 (86%) | 3 (80%) | 4 (76%) | 5 (72%) | 6 (68%) | 7 (66%) | 8 (54%) | 9 (50%) | 10 (44%) |



Robertson et al., 2012

Conclusion

- HIE trigger is poorly understood → **public health issue**
- More than 1M deaths and 2M infants with neurocognitive impairments / year
- **Therapeutic hypothermia** is feasible, safe in referral centers and efficient at mid-term if initiated before 6h of life ... **but impact in long-term outcomes?**
- **Hot topics for neuroprotective strategies**
- ... **the future** → combination of hypothermia + other pharmacological agent(s)

